Literature DB >> 2115148

[3H]ketanserin binds to non-5-HT2 sites in rabbit cerebral cortex and neostriatum.

K M Dewar1, L Lima, T A Reader.   

Abstract

A characterization of [3H]ketanserin ([3H]KTS) binding in the frontal cortex (fCTX) and neostriatum (caudate-putamen, CPU) of rabbit was carried out to determine whether this ligand labels a non-serotoninergic receptor. The association and dissociation kinetics in fCTX were rapid, and could be fitted to two-site models, suggesting [3H]KTS is labeling two cortical sites. Using the serotonin-2 (5-HT2) antagonist mianserin to determine nonspecific binding, the saturation curves revealed a single high-affinity binding site. In contrast, when unlabeled ketanserin was used for nonspecific counts, the Scatchard plots were best fitted to a two-site model but the binding parameters of the high-affinity site were similar to that obtained in the presence of mianserin. The 5-HT2 antagonists mianserin, methysergide and ritanserin inhibited [3H]KTS binding in fCTX at nanomolar concentrations, however, the curves were best fitted to two-site models. In contrast, [3H]KTS binding to membrane preparations from the CPU could only be inhibited by high (micromolar) concentrations of these antagonists. Low micromolar concentrations of the monoamine uptake blockers GBR12909, desipramine, nomifensine, cocaine and fluoxetine competed with [3H]KTS in both fCTX and CPU. This study demonstrates that [3H]KTS labels a non-serotoninergic recognition site in the rabbit fCTX and CPU similar to that found in the rat neostriatum, i.e.: probably a monoamine transport site.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2115148     DOI: 10.1007/bf00966208

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  12 in total

1.  Distribution of monoamines and metabolites in rabbit neostriatum, hippocampus and cortex.

Authors:  T A Reader; K M Dewar; L Grondin
Journal:  Brain Res Bull       Date:  1989-09       Impact factor: 4.077

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Evidence for distinct 5-hydroxytryptamine2 binding site subtypes in cortical membrane preparations.

Authors:  P A Pierce; S J Peroutka
Journal:  J Neurochem       Date:  1989-02       Impact factor: 5.372

4.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC.

Authors:  G A McPherson
Journal:  J Pharmacol Methods       Date:  1985-11

5.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

6.  [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role.

Authors:  J E Leysen; C J Niemegeers; J M Van Nueten; P M Laduron
Journal:  Mol Pharmacol       Date:  1982-03       Impact factor: 4.436

7.  Endogenous homovanillic acid levels differ between rat and rabbit caudate, hippocampus, and cortical regions.

Authors:  T A Reader; K M Dewar
Journal:  Neurochem Res       Date:  1989-11       Impact factor: 3.996

8.  Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors.

Authors:  A Pazos; R Cortés; J M Palacios
Journal:  Brain Res       Date:  1985-11-04       Impact factor: 3.252

9.  (R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes.

Authors:  S J Peroutka; A Hamik; M A Harrington; A J Hoffman; C A Mathis; P A Pierce; S S Wang
Journal:  Mol Pharmacol       Date:  1988-10       Impact factor: 4.436

10.  [3H]ketanserin labels 5-HT2 receptors and alpha 1-adrenoceptors in human and pig brain membranes.

Authors:  D Hoyer; P Vos; A Closse; A Pazos; J M Palacios; H Davies
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.